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Abstract
Prognosis for patients with the human immunodeficiency virus (HIV) has improved with the
introduction of highly active antiretroviral therapy (HAART). Evidence over recent years suggests
that the incidence of cardiovascular disease is increasing in HIV patients. The ankle-brachial index
(ABI) is a cheap and easy test that has been validated in the general population. Abnormal ABI
values are associated with increased cardiovascular mortality. To date, six series of ABI values in
persons with HIV have been published, but none was a prospective study. No agreement exists
concerning the risk factors for an abnormal ABI, though its prevalence is clearly higher in these
patients than in the general population. Whether this higher prevalence of an abnormal ABI is
associated with a higher incidence of vascular events remains to be determined.
Introduction
The generalised use of highly active antiretroviral therapy
(HAART) in patients with the human immunodeficiency
virus (HIV) has led to a spectacular increase in their sur-
vival rates [1-3]. At the same time, several cohort studies
have noted an increase in the relative risk of major cardi-
ovascular events, especially acute myocardial infarction
and subclinical vascular disease [4-8]. Pathophysiological
evidence exists that both HIV and HAART can affect the
lipid profile [9,10], insulin resistance [11,12] and the vas-
cular response to vasodilatation [13]. This has led to
greater interest among physicians attending these patients
in earlier diagnosis and treatment of the traditional cardi-
ovascular risk factors, and recommendations have even
been made for proactive changes in HAART, with a view
to improving the profile of these risk factors [14].
Cohort studies have revealed an increase in the relative
risk of acute myocardial infarction and cardiovascular dis-
ease, which has not yet been reflected in a large number of
cases because absolute levels of incidence remain low
[15,16]. Nevertheless, the incidence observed is greater
than that expected according to predictive techniques
such as Framingham's equation [17]. Given the possibility
that in a few years cardiovascular disease among HIV
patients will become more significant than at present, it is
of interest to make use of diagnostic tests that enable the
early identification of groups of patients presenting high
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vascular risk, so that a closer control may be maintained
of cardiovascular disease risk factors. Cardiovascular dis-
ease is the fourth cause of death among HIV patients,
close behind non-AIDS-associated neoplasias [18]. Ide-
ally, such tests should be cheap, comparable, innocuous
and applicable at outpatient clinics. Techniques for the
early diagnosis of atherosclerotic diseases in these patients
would enable persons at high risk of cardiovascular events
to receive more aggressive therapy for the management of
these risk factors and even enable proactive changes in
their HAART to be made.
In this context, it is of interest to examine techniques such
as measuring the carotid artery intima-media thickness
(IMT) or the ankle-brachial index (ABI). The latter index
reflects the relation between systolic arterial tension meas-
ured in the upper and in the lower limbs; values lower
than 0.9 or higher than 1.3, according to guidelines to
clinical practice [19], are considered pathologic and asso-
ciated with a higher incidence of vascular morbimortality.
A recent meta-analysis of the general population, using
the ABI index, found an association of values of ≤ 1.1 or ≥
1.4 with an increased risk of cardiovascular disease and
death [20]. This meta-analysis considered 16 studies with
a total of 480,325 patients-year, and concluded that an
ABI ≤0.9 was associated with a doubled risk of 10-year
global mortality, of cardiovascular mortality and of the
incidence of severe coronary events, in comparison with
the predictions derived from Framingham's equation. In
fact, the application of the ABI test to patients previously
stratified for vascular risk by Framingham's equation
resulted in the reclassification of almost 19% of male
patients and of 36% of female patients, and the conse-
quent modification of treatment recommendations for
these patients. As remarked above, current American clin-
ical practice guidelines for peripheral arterial disease con-
sider an abnormal ABI to be <0.9 or ≥1.3. The technique
is cheap, harmless and reproducible, with a predictable
inter-examiner variation [21]. In this short review, we ana-
lyze the series published on the application of ABI tests
among HIV-infected populations.
Analysis of Published Series
To date, six series have been published on patients with
HIV infection and for whom the ABI was calculated. As
shown in Table 1, the series are heterogeneous for both
the type of patients (sex and age) and for the ABI measure-
ment. The selection of patients was also very heterogene-
ous; Periard et al [22] selected patients referred from
outpatient clinics, aged over 40 years, after having
excluded active drug addicts and those patients with pre-
vious arterial complications; Palacios et al [23] selected
patients aged over 50 years, and Bernal et al [24], those
with two or more traditional cardiovascular risk factors;
Sharma et al [25] included only women patients, while
Gutiérrez et al [26] and Olalla et al [27] did not exclude
any type of patient and did not report any conditions for
inclusion. In all cases, however, the patients had been
referred from HIV infection clinics. Only two of the series
reported the number of patients with a high ABI [25,27],
whereas all the series recorded the prevalence of an ABI
<0.9. Table 2 shows the different rates of prevalence of the
traditional cardiovascular risk factors in the various
cohorts.
Both Sharma and Palacios [23,25] compared the preva-
lence of altered ABI in patients with and without HIV
infection, although among very different types of patients.
Sharma et al [25] compared HIV-infected women aged, on
average, 39.6 years with non-infected women aged, on
average, 36.4 years (p = 0.002) and found the infected
women to include a higher proportion of patients with
HDL cholesterol ≤35 mg/dl (26.2% vs 5.2%, p < 0.001)
and of triglycerides ≥200 mg/dl (13.4% vs 5.2%, p =
Table 1: Prevalence of abnormal ABI in each series
Study Type of patients N Male (%) Age in years
(mean)
ABI≤0.9
N (%)
ABI≥1.3
N (%)
ABI≥1.4
N (%)
Sharma et al. [25] Women (73.9% black) 238 0 39.6 3 (0.9)a NM 17 (7.2)
Periard et al. [22] Age >40 years 92 76.1 49.5 19
(20.7)b
NM NM
Bernal et al. [24] With ≥2 CVRF 91 87.9 50 4 (4.39) NM NM
Gutiérrez et al. [26] Consecutive patients 139 72.7 45.8 4 (2.88) NM 4 (2.88)
Palacios et al. [23] Age ≥50 years 99 82.8 58.6 10 (10.2) NM NM
Olalla et al. [27] Consecutive patients 147 82.3 43.9 4 (2.7) 29 (19.7) 8 (5.4)c
a: the prevalence of 0.9% refers to the joint cohort of women with and without HIV (total of 335 patients). No report is given of the separate 
prevalence for each group.
NM: not mentioned.
b: the prevalence includes ABI <0.9 at rest and after exercise (9.8% and 10.9%, respectively).
CVRF: cardiovascular risk factors
NM: not mentioned.
c: data not published; the report only refers to the total number of patients with ABI <0.9 or >1.3.AIDS Research and Therapy 2009, 6:6 http://www.aidsrestherapy.com/content/6/1/6
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0.03). However, despite the difference in age and the
poorer metabolic profile of HIV-infected patients, the
prevalence of increased ABI was similar (7.2% among HIV
infected patients vs 6.3% among non-infected patients).
The prevalence of low ABI was only 0.9% (among the two
groups of patients). The series analyzed by Palacios et al
[23] was constituted basically of male patients (82.8%),
with the HIV-group presenting a higher proportion of
smokers (30.3% vs 46.5%, p = 0.02), and a higher body
mass index (24.8 kg/m2 vs 27.7 kg/m2, p = 0.0001), while
the HIV+ group presented a higher proportion of patients
with hyperlipemia (69.4% vs 36.7%, p = 0.0001), diabe-
tes (31.3% vs 12.2%, p = 0.002) and cardiovascular risk
>20% calculated by Framingham's equation (29.5% vs
13.4%, p = 0.008). The prevalence of ABI <0.9 was signif-
icantly greater among the HIV+ patients than among
those not so infected (10.2% vs 1%, p = 0.01).
All the studies were cut-off studies, and no follow-up
study has yet been made. Only Gutiérrez et al [26] studied
the association between an abnormal ABI and a marker of
cardiovascular disease, the carotid artery intima-media
thickness (IMT). They found that an ABI <0.9 was associ-
ated with an increased IMT, though the same was not
found for patients with an ABI >1.4. Except Sharma et al
[25], the studies have been conducted mainly in men.
As regards factors associated with an abnormal ABI,
Sharma et al. undertook a multivariate analysis of a group
of women with and without HIV. They established that
cigarette smoking (OR: 2.53; 95% CI, 0.99–6.43), a body
mass index <18.5 (OR: 11; 95% CI, 1.61–75.63) and over-
weight (OR 5.4; 95% CI, 1.13–25.89) were all associated
with an increased ABI. Periard et al [22] found that factors
predicting a low ABI were age (OR 1.09; 95% CI, 1–1.18,
for each additional year), cigarette smoking (OR 1.7; 95%
CI, 1.17–2.46, for each additional 10 pack-years), diabe-
tes (with a perfect prediction, as all the diabetic patients
included in the multivariate analysis had a low ABI) and
a CD4 cell count below 200 cells per microlitre (OR 27.2;
95% CI, 2.55–286.01). Bernal et al [24] and Palacios et al
[23] found no significant association with a low ABI. A
univariate analysis by Gutiérrez et al [26] of factors related
with a low ABI found significant differences between the
number of classical cardiovascular factors (4 in patients
with a low ABI versus 2 in the others, p = 0.015) and a
lower CD4 cell count (220 vs. 450 cells per microlitre, p =
0.009). In their multivariate analysis, Olalla et al [27]
related it with the use of protease inhibitors (OR 2.79;
95% CI, 1.15–6.54) and the presence of dyslipidemia (OR
2.68; 95% CI, 1.06–6.91); this study, too, found a signifi-
cant difference in CD4 cells in patients with an abnormal
ABI (185.64 vs. 266.67 cells/mL, p = 0.03).
Discussion
The prevalence of an abnormal ABI in patients with HIV is
greater than in the general population, especially regard-
ing those with a high ABI. It remains to be determined
whether the current cut-off points for the non-infected
population (which leave out the population at risk, such
as those with an ABI between 0.9 and 1.1) have the same
value in the population with HIV. These cut-off points
need to be validated with follow-up studies on the inci-
dence of major ischemic cardiovascular events. Analysis of
the different series clearly shows that the prevalence of an
abnormal ABI is far more frequent in persons with HIV
compared with the general population, in whom the prev-
alence of peripheral arterial disease is estimated to be 1%
at the age of 50 years and 3% at the age of 60 [28,29].
Of note in our patients was the high prevalence of an ABI
>1.3 or >1.4. Whilst the prevalence of an ABI <0.9 is
higher in HIV infected persons than among the general
population, a high ABI is even more prevalent. A meta-
analysis recently published by the Ankle Brachial Index
Collaboration [20] showed that an ABI ≥1.4 was associ-
ated with greater overall mortality and cardiovascular
mortality in both men and women; this association was
not found for an ABI ≥1.3. The same deleterious associa-
tion was also established for an ABI ≤ 1.1. Clinical practice
Table 2: Prevalence of traditional vascular risk factors in each series.
Risk factor (prevalence in %) Sharma et al [25] Periard et al [22] Bernal et al [24] Gutiérrez et al [26] Palacios et al [23] Olalla
et al [27]
Diabetes 9.7 4.3 17.6 10.1 31.3 2
Hypertension 23.4 27.2 57.1 28.8 36.4 4.1
Dyslipidaemia NM NM 69.2 NM 69.4 18.4
Hypertriglyceridemia 13.4 35.9 NM NM NM NM
High LDL cholesterol 6 17.4 NM NM NM NM
Low HDL cholesterol 26.2 13 NM NM NM NM
Cigarette smoking 43.5 62 72.5 61.1 30.3 59.9
Family history of cardiovascular 
events
NM 22.8 19.8 10.8 15.2 2.7
NM: not mentioned.AIDS Research and Therapy 2009, 6:6 http://www.aidsrestherapy.com/content/6/1/6
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guidelines, however, still retain the cut-off points of 0.9
and 1.3 when referring to a pathological ABI [19].
The prevalence of altered ABI varies greatly among the dif-
ferent series analyzed. At one extreme is that of Periard
[22], who reported a prevalence of ABI <0.9 of 20.7%. The
selection criterion used in this case was merely that of
patients aged over 40 years, even though the average age
was in fact close to 50 years. The reason for this high rate
of prevalence may lie in the fact that 15% of the patients
in this series reported intermittent claudication, according
to the Edinburgh questionnaire, which inclines us to
believe that selection bias may be present. At the other
extreme is the series described by Sharma [25], in which
the prevalence of ABI <0.9 was only 0.9%; this value cor-
responded to a group of women with an average age of
less than 40 years.
Studies such as those by Periard [22], Gutiérrez [26] and
Olalla [27] suggest a possible association between a
higher degree of immunosuppression and altered ABI.
The first of these authors assigned an OR of 27 to obtain
an altered ABI if CD4 < 200 cells/microlitre, while Gutiér-
rez and Olalla found a significant difference in the CD4
lymphocyte cell count between altered and non-altered
ABI. Studies have been made of other subordinate mark-
ers, such as the carotid intima-media thickness; these, too,
relate one-year progression with higher levels of immuno-
suppression. HIV itself has revealed an inverse relation
between the level of viral load and endothelium-mediated
vasodilation, and also with components of the antiretro-
viral treatment applied, such as protease inhibitors or
abacavir [13,30]. This would account for findings such as
those for Olalla's series [27], in which protease inhibitors
were associated with altered ABI, this effect being control-
led by the presence of dyslipidaemia. Periard [22]
reported an OR of 1.03, with no statistically significant
association, with the accumulated use of protease inhibi-
tors.
Smoking has been associated with both a low ABI and
with a high ABI, probably because, on the one hand, it is
involved in the generation and progression of atheroma-
tous plaques, while on the other; it affects the elasticity of
the arterial wall.
This same toxicity towards the endothelium, expressed as
the induction of apoptosis (ritonavir) or as the stimula-
tion of endothelium-mediated vasodilation, may partially
account for the relation between the use of protease inhib-
itors with altered ABI, especially due to the lack of arterial
compliance (ABI >1.3) rather than because of pure steno-
sis of the arterial lumen (ABI <0.9). Thus, the high preva-
lence of a high ABI may be mediated by the involvement
of vascular elasticity as well as by the generation of
atheroma plaques.
All the series published show a prevalence of altered ABI
that is much greater than that of the rates of peripheral
arterial disease observed among the general population:
1% at the age of 50 years and 3% at 60 years. If large series
confirm this finding, a greater and earlier incidence of vas-
cular events would be expected among the HIV-infected
population. Indeed, various studies have already reported
a greater and earlier incidence of cardiovascular disease
among these patients [31,32].
Framingham's equation underestimates the vascular risk
affecting HIV-infected patients [17]. If ABI measuring
becomes generalised, those patients with pathological val-
ues should be considered to be at high cardiovascular risk
and hence management of cardiovascular risk factors
should be more aggressive than usual.
Conclusion
Vascular risk has become an important issue in HIV
infected people. Prevalence of abnormal ABI appears to be
higher in these patients, and PI use could be in relation-
ship with this. Generalized use of ABI could be an inter-
esting way to identify patients with high vascular risk.
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